Voxilaprevir | CAS#1535212-07-7 | HCV protease inhibitor

MedKoo Cat#: 562012 | Name: Voxilaprevir

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Voxilaprevir is a pan-genotypic hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease inhibitor. It inhibits replication of wild-type HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a (EC50s = 1.9-6.6 nM in replicon assays). Voxilaprevir also inhibits replication of mutant HCV genotypes containing NS3 resistance-associated substitutions (EC50s = 3.1, 2.7, and 4 nM for HCV genotypes 1a Q80K, 1a R155K, and 1b D168E, respectively). Formulations containing Voxilaprevir have been used in the treatment of chronic HCV infection.

Chemical Structure

Voxilaprevir

CAS#1535212-07-7

Theoretical Analysis

MedKoo Cat#: 562012

Name: Voxilaprevir

CAS#: 1535212-07-7

Chemical Formula: C40H52F4N6O9S

Exact Mass: 868.3453

Molecular Weight: 868.94

Elemental Analysis: C, 55.29; H, 6.03; F, 8.75; N, 9.67; O, 16.57; S, 3.69

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 850.00	2 Weeks
10mg	USD 1,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Voxilaprevir; GS-9857; GS 9857; GS9857; Vosevi;

IUPAC/Chemical Name

(33R,34S,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide

InChi Key

MZBLZLWXUBZHSL-FZNJKFJKSA-N

InChi Code

InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1

SMILES Code

COC(C=C1)=CC2=C1N=C(C(O[C@@H](C3)[C@@H](CC)[C@@H](C(N[C@]4(C(NS(=O)(C5(C)CC5)=O)=O)C[C@H]4C(F)F)=O)N3C6=O)=N2)C(F)(F)CCCC[C@H]7[C@@H](C7)OC(N[C@H]6C(C)(C)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	34.52
	DMSO	30.0	34.52
	Ethanol	1.0	1.15

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 868.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med. 2021 Apr 8;10(8):1568. doi: 10.3390/jcm10081568. PMID: 33917830; PMCID: PMC8068207. 2: Garcia-Cehic D, Rando A, Rodriguez-Frias F, Gregori J, Costa JG, Carrión JA, Macenlle R, Pamplona J, Castro-Iglesias A, Cañizares A, Tabernero D, Campos C, Buti M, Esteban JI, Quer J. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure. J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13497. Epub ahead of print. PMID: 33720484. 3: Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. J Hepatol. 2021 Mar 12:S0168-8278(21)00169-0. doi: 10.1016/j.jhep.2021.03.004. Epub ahead of print. PMID: 33716089. 4: Onofrio FQ, Cooper C, Borgia SM, Vachon ML, Ramji A, Lilly LB, Wong A, Booth J, Sattar I, Morales H, Lee S, Conway B, Feld JJ. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. Clin Infect Dis. 2021 Mar 2:ciaa1510. doi: 10.1093/cid/ciaa1510. Epub ahead of print. PMID: 33677545. 5: Boff da Costa R, Boff Costa M, Longo L, Miotto DE, Hirata Dellavia G, Trucollo Michalczuk M, Reis Álvares-da-Silva M. Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications. PLoS One. 2021 Feb 12;16(2):e0245767. doi: 10.1371/journal.pone.0245767. PMID: 33577593; PMCID: PMC7880426. 6: Gao LH, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct- Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med. 2021 Jan 28;14:289-301. doi: 10.2147/IJGM.S283910. PMID: 33536776; PMCID: PMC7850569. 7: Choi C, Botros Y, Shah J, Xue P, Jones A, Galan M, Olivo R, Niazi M, Paterno F, Guarrera J, Pyrsopoulos NT. A Case Report of Alloimmune Hepatitis after Direct-acting Antiviral Treatment in a Liver Transplant Patient. J Clin Transl Hepatol. 2020 Dec 28;8(4):459-462. doi: 10.14218/JCTH.2020.00062. Epub 2020 Oct 10. PMID: 33447530; PMCID: PMC7782114. 8: Higley C, Hsu CC, Smith C, Nadella S, Lalos AT. Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports. World J Hepatol. 2020 Dec 27;12(12):1341-1348. doi: 10.4254/wjh.v12.i12.1341. PMID: 33442459; PMCID: PMC7772723. 9: Rožnovský L, Mrázek J, Petroušová L, Orságová I, Kabieszová L, Konečná M, Kloudová A. [Two case reports of chronic hepatitis C retreatment]. Klin Mikrobiol Infekc Lek. 2020 Sep;26(3):96-98. Czech. PMID: 33418597. 10: Sicras-Mainar A, Morillo-Verdugo R. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection. Adicciones. 2020 Dec 5;0(0):1551. English, Spanish. doi: 10.20882/adicciones.1551. Epub ahead of print. PMID: 33338248. 11: Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, Yu ML. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Clin Mol Hepatol. 2021 Jan;27(1):186-196. doi: 10.3350/cmh.2020.0180. Epub 2020 Dec 3. PMID: 33317251; PMCID: PMC7820195. 12: Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19. PMID: 33220331. 13: Sicras-Mainar A, Morillo-Verdugo R. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. J Int Med Res. 2020 Oct;48(10):300060520964659. doi: 10.1177/0300060520964659. PMID: 33111612; PMCID: PMC7645390. 14: Hong J, Wright RC, Partovi N, Yoshida EM, Hussaini T. Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents. J Clin Transl Hepatol. 2020 Sep 28;8(3):322-335. doi: 10.14218/JCTH.2020.00034. Epub 2020 Jul 30. PMID: 33083256; PMCID: PMC7562806. 15: Zhuang L, Li J, Zhang Y, Ji S, Li Y, Zhao Y, Li B, Li W, Quan M, Duan Y, Zhao H, Cheng D, Wang X, Ou W, Xing H. Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis. Ann Hepatol. 2020 Oct 12;23:100268. doi: 10.1016/j.aohep.2020.09.012. Epub ahead of print. PMID: 33059055. 16: Vermehren J, Serfert Y, Cornberg M, Stoehr A, Klinker H, Simon KG, Teuber G, Deterding K, Schulze Zur Wiesch J, Jung MC, Manns MP, Zeuzem S, Wedemeyer H, Sarrazin C. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). Z Gastroenterol. 2020 Sep;58(9):841-846. English. doi: 10.1055/a-1217-7669. Epub 2020 Sep 18. PMID: 32947629. 17: Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, MacQuillan G, Dore GJ, Wade AJ, George J, Hazeldine S, O'Beirne J, Wigg A, Fisher L, McGarity B, Sawhney R, Sinclair M, Thomas J, Valiozis I, Weltman M, Wilson M, Woodward A, Ahlenstiel G, Haque M, Levy M, Prewett E, Sievert W, Sood S, Tse E, Valaydon Z, Bowden S, Douglas M, New K, O'Keefe J, Hellard M, Doyle J, Stoove M, Thompson AJ. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. Clin Infect Dis. 2020 Sep 5:ciaa1318. doi: 10.1093/cid/ciaa1318. Epub ahead of print. PMID: 32887983. 18: Bellesini M, Bianchin M, Corradi C, Donadini MP, Raschi E, Squizzato A. Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. Clin Drug Investig. 2020 Nov;40(11):1001-1008. doi: 10.1007/s40261-020-00962-y. PMID: 32809123; PMCID: PMC7595962. 19: Ruiz-Boy S, Rodriguez-Reyes M, Sotoca-Momblona JM. Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals. Med Clin (Barc). 2020 Aug 14:S0025-7753(20)30507-8. English, Spanish. doi: 10.1016/j.medcli.2020.05.054. Epub ahead of print. PMID: 32807510. 20: de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304. PMID: 32772078.